Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants-Reference-Cited by-同舟云学术

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Published:2020-01-27 Issue:2 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Fraile-Ribot Pablo A.¹,Zamorano Laura¹,Orellana Rocío¹,del Barrio-Tofiño Ester¹,Sánchez-Diener Irina¹,Cortes-Lara Sara¹,López-Causapé Carla¹,Cabot Gabriel¹^ORCID,Bou Germán²,Martínez-Martínez Luis³,Oliver Antonio¹^ORCID,

Affiliation:

1. Servicio de Microbiología, Hospital Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain

2. Servicio de Microbiología, Hospital Universitario La Coruña, Instituto Investigación Biomédica A Coruña (INIBIC), A Coruna, Spain

3. Unidad de Gestión Clínica de Microbiología, Hospital Reina Sofía, Departamento de Microbiología, Universidad de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba, Spain

Abstract

Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02165-19

Reference16 articles.

1. Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections

2. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

3. The increasing threat of Pseudomonas aeruginosa high-risk clones

4. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

5. Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa;Diagnostic Microbiology and Infectious Disease;2024-12

2. Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria;Communications Medicine;2024-08-29

3. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

4. Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis;Current Therapeutic Research;2024

5. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa;European Journal of Clinical Microbiology & Infectious Diseases;2023-12-29